Healthcare / BiotechnologyNasdaqCM
$12.12
+0.68 (+5.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-37.0M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$231M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-2418.8%
↓Gross Margin
N/A
•Debt/Equity
8.87
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-39.6M · FCF $-37.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | $28.3M | $2.9M |
| Net Income | $-39.6M | $-39.6M | $-51.9M | $-35.2M | $-28.2M | $-54.6M | $-80.1M |
| EBITDA | $-37.3M | $-37.3M | $-50.3M | $-33.0M | $-23.6M | — | — |
| EPS | -2.58 | -2.58 | -4.25 | -6.96 | -2.70 | -19.30 | -54.30 |
| Operating Margin | — | — | — | — | — | -138.8% | -1919.2% |
| Net Margin | — | — | — | — | — | -192.8% | -2781.5% |
| Balance Sheet | |||||||
| Debt/Equity | 8.87 | 8.87 | -2.30 | 0.61 | -0.07 | 0.00 | -0.01 |
| Current Ratio | 2.24 | 2.24 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-37.0M | $-37.0M | $-37.2M | $-32.8M | $-22.8M | $-53.0M | $-22.9M |
| Returns | |||||||
| ROE | -2418.8% | -2418.8% | 458.8% | -309.5% | 27.6% | 73.2% | 88.6% |
| Valuation | |||||||
| P/B | 113.44 | 113.44 | — | 3.16 | — | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | — | — | 883.1% | — |
| EPS Growth | 39.3% | 39.3% | 38.9% | -158.2% | — | 64.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+67.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.25 → -2.58
Residual
+67.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.